|
1
|
Chiba T, Ohtani H, Mizoi T, Naito Y, Sato
E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y and Satomi S:
Intraepithelial CD8+ T-cell-count becomes a prognostic factor after
a longer follow-up period in human colorectal carcinoma: Possible
association with suppression of micrometastasis. Br J Cancer.
91:1711–1717. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Diederichsen AC, Hjelmborg Jv, Christensen
PB, Zeuthen J and Fenger C: Prognostic value of the CD4+/CD8+ ratio
of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR
expression on tumour cells. Cancer Immunol Immunother. 52:423–428.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Funada Y, Noguchi T, Kikuchi R, Takeno S,
Uchida Y and Gabbert HE: Prognostic significance of CD8+ T cell and
macrophage peritumoral infiltration in colorectal cancer. Oncol
Rep. 10:309–313. 2003.PubMed/NCBI
|
|
4
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within
cancer cell nests as a prognostic factor in human colorectal
cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
|
|
5
|
Oberg A, Samii S, Stenling R and Lindmark
G: Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in
regional lymph node metastases from colorectal cancer as potential
prognostic predictors. Int J Colorectal Dis. 17:25–29. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ropponen KM, Eskelinen MJ, Lipponen PK,
Alhava E and Kosma VM: Prognostic value of tumour-infiltrating
lymphocytes (TILs) in colorectal cancer. J Pathol. 182:318–324.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagorsen D, Keilholz U, Rivoltini L,
Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E and
Scheibenbogen C: Natural T-cell response against MHC class I
epitopes of epithelial cell adhesion molecule, her-2/neu, and
carcinoembryonic antigen in patients with colorectal cancer. Cancer
Res. 60:4850–4854. 2000.PubMed/NCBI
|
|
8
|
Nagorsen D, Scheibenbogen C, Marincola FM,
Letsch A and Keilholz U: Natural T cell immunity against cancer.
Clin Cancer Res. 9:4296–4303. 2003.PubMed/NCBI
|
|
9
|
Nagorsen D, Scheibenbogen C, Letsch A,
Germer CT, Buhr HJ, Hegewisch-Becker S, Rivoltini L, Thiel E and
Keilholz U: T cell responses against tumor associated antigens and
prognosis in colorectal cancer patients. J Transl Med. 3:32005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blankenstein T: The role of tumor stroma
in the interaction between tumor and immune system. Curr Opin
Immunol. 17:180–186. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kinnula VL, Torkkeli T, Kristo P, Sormunen
R, Soini Y, Pääkkö P, Ollikainen T, Kahlos K, Hirvonen A and
Knuutila S: Ultrastructural and chromosomal studies on manganese
superoxide dismutase in malignant mesothelioma. Am J Respir Cell
Mol Biol. 31:147–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kojima M, Morisaki T, Tsukahara Y,
Uchiyama A, Matsunari Y, Mibu R and Tanaka M: Nitric oxide synthase
expression and nitric oxide production in human colon carcinoma
tissue. J Surg Oncol. 70:222–229. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura Y, Yasuoka H, Tsujimoto M,
Yoshidome K, Nakahara M, Nakao K, Nakamura M and Kakudo K: Nitric
oxide in breast cancer: Induction of vascular endothelial growth
factor-C and correlation with metastasis and poor prognosis. Clin
Cancer Res. 12:1201–1207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ahmed B and Van Den Oord JJ: Expression of
the inducible isoform of nitric oxide synthase in pigment cell
lesions of the skin. Br J Dermatol. 142:432–440. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Masri FA, Comhair SA, Koeck T, Xu W,
Janocha A, Ghosh S, Dweik RA, Golish J, Kinter M, Stuehr DJ, et al:
Abnormalities in nitric oxide and its derivatives in lung cancer.
Am J Respir Crit Care Med. 172:597–605. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vakkala M, Kahlos K, Lakari E, Pääkkö P,
Kinnula V and Soini Y: Inducible nitric oxide synthase expression,
apoptosis, and angiogenesis in in situ and invasive breast
carcinomas. Clin Cancer Res. 6:2408–2416. 2000.PubMed/NCBI
|
|
17
|
Kono K, Salazar-Onfray F, Petersson M,
Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P and
Kiessling R: Hydrogen peroxide secreted by tumor-derived
macrophages down-modulates signal-transducing zeta molecules and
inhibits tumor-specific T cell-and natural killer cell-mediated
cytotoxicity. Eur J Immunol. 26:1308–1313. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rotondo R, Mastracci L, Piazza T,
Barisione G, Fabbi M, Cassanello M, Costa R, Morandi B, Astigiano
S, Cesario A, et al: Arginase 2 is expressed by human lung cancer,
but it neither induces immune suppression, nor affects disease
progression. Int J Cancer. 123:1108–1116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jochems C and Schlom J: Tumor-infiltrating
immune cells and prognosis: The potential link between conventional
cancer therapy and immunity. Exp Biol Med (Maywood). 236:567–579.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic significance in
colorectal cancer. J Clin Oncol. 27:186–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Di Giorgio A, Botti C, Tocchi A,
Mingazzini P and Flammia M: The influence of tumor lymphocytic
infiltration on long term survival of surgically treated colorectal
cancer patients. Int Surg. 77:256–260. 1992.PubMed/NCBI
|
|
23
|
Nzula S, Going JJ and Stott DI:
Antigen-driven clonal proliferation, somatic hypermutation, and
selection of B lymphocytes infiltrating human ductal breast
carcinomas. Cancer Res. 63:3275–3280. 2003.PubMed/NCBI
|
|
24
|
Biswas SK and Mantovani A: Macrophage
plasticity and interaction with lymphocyte subsets: Cancer as a
paradigm. Nat Immunol. 11:889–896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fleetwood AJ, Lawrence T, Hamilton JA and
Cook AD: Granulocyte-macrophage colony-stimulating factor (CSF) and
macrophage CSF-dependent macrophage phenotypes display differences
in cytokine profiles and transcription factor activities:
Implications for CSF blockade in inflammation. J Immunol.
178:5245–5252. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gordon S and Martinez FO: Alternative
activation of macrophages: Mechanism and functions. Immunity.
32:593–604. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mantovani A, Sica A and Locati M:
Macrophage polarization comes of age. Immunity. 23:344–346. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martinez FO, Gordon S, Locati M and
Mantovani A: Transcriptional profiling of the human
monocyte-to-macrophage differentiation and polarization: New
molecules and patterns of gene expression. J Immunol.
177:7303–7311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Martinez FO, Helming L and Gordon S:
Alternative activation of macrophages: An immunologic functional
perspective. Annu Rev Immunol. 27:451–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stein M, Keshav S, Harris N and Gordon S:
Interleukin 4 potently enhances murine macrophage mannose receptor
activity: A marker of alternative immunologic macrophage
activation. J Exp Med. 176:287–292. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krausgruber T, Blazek K, Smallie T,
Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M and Udalova
IA: IRF5 promotes inflammatory macrophage polarization and TH1-TH17
responses. Nat Immunol. 12:231–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Satoh T, Takeuchi O, Vandenbon A, Yasuda
K, Tanaka Y, Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh
T, et al: The Jmjd3-Irf4 axis regulates M2 macrophage polarization
and host responses against helminth infection. Nat Immunol.
11:936–944. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brunschwig A: The Efficacy of ‘Coley's
Toxin’ in the Treatment of Sarcoma: An experimental study. Ann
Surg. 109:109–113. 1939. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maletzki C, Klier U, Obst W, Kreikemeyer B
and Linnebacher M: Reevaluating the concept of treating
experimental tumors with a mixed bacterial vaccine: Coley's toxin.
Clin Dev Immunol. 2012:2306252012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao E, Maj T, Kryczek I, Li W, Wu K, Zhao
L, Wei S, Crespo J, Wan S, Vatan L, et al: Cancer mediates effector
T cell dysfunction by targeting microRNAs and EZH2 via glycolysis
restriction. Nat Immunol. 17:95–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peng D, Kryczek I, Nagarsheth N, Zhao L,
Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al: Epigenetic
silencing of TH1-type chemokines shapes tumour immunity and
immunotherapy. Nature. 527:249–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
